| |
Unadjusted
|
Adjusted
|
|---|
|
CT/TT
|
CC
|
Pa
|
aOR (95% CI)
|
pb
|
|---|
|
(A) rs6897932
|
|
F ≥ 3
|
20.5% (17/83)
|
23.4% (32/137)
|
0.619
|
1.14 (0.54;2.32)
|
0.735
|
|
APRI ≥1.5
|
15% (12/80)
|
18.6% (24/129)
|
0.502
|
1.14 (0.48;2.68)
|
0.770
|
|
FIB4 ≥3.25
|
10% (8/80)
|
9.3% (12/129)
|
0.868
|
0.80 (0.25;2.56)
|
0.705
|
|
A3
|
4.9% (4/82)
|
14.9% (20/134)
|
0.023
|
4.16 (1.19;14.59)
|
0.026
|
| |
Unadjusted
|
Adjusted
|
|---|
|
AA/AT
|
TT
|
Pa
|
aOR (95% CI)
|
pb
|
|---|
|
(B) rs987106
|
|
F ≥ 3
|
18.8% (32/170)
|
34.7% (17/49)
|
0.019
|
3.09 (1.32;7.22)
|
0.009
|
|
APRI ≥1.5
|
14.3% (23/161)
|
27.7% (13/47)
|
0.033
|
1.84 (0.72;4.70)
|
0.201
|
|
FIB4 ≥3.25
|
7.5% (12/161)
|
17% (8/47)
|
0.050
|
2.33 (0.67;8.05)
|
0.181
|
|
A3
|
10.1% (17/168)
|
14.9% (7/47)
|
0.358
|
1.82 (0.63;5.23)
|
0.269
|
| |
Unadjusted
|
Adjusted
|
|---|
|
AG/GG
|
AA
|
Pa
|
aOR (95% CI)
|
pb
|
|---|
|
(C) rs3194051
|
|
F ≥ 3
|
16.7% (20/120)
|
29.3% (29/99)
|
0.026
|
2.73 (1.22;5.87)
|
0.010
|
|
APRI ≥1.5
|
11.5% (13/113)
|
24.2% (23/95)
|
0.016
|
2.52 (1.10;5.77)
|
0.029
|
|
FIB4 ≥3.25
|
5.3% (6/113)
|
14.7% (14/95)
|
0.022
|
4.01 (1.17;13.71)
|
0.027
|
|
A3
|
12.6% (15/119)
|
9.4% (9/96)
|
0.455
|
0.79 (0.30;2.10)
|
0.634
|
- Statistically significant differences are shown in italics.
-
HCV hepatitis C virus, HIV human immunodeficiency virus, CHC chronic hepatitis C, 95% CI 95% of confidence interval, aOR adjusted odds ratio, p value level of significance, A3 severe activity grade (Metavir), F ≥ 3 advanced liver fibrosis (Metavir), APRI aspartate aminotransferase to platelet ratio index.
-
ap values were calculated by Chi squared test.
-
bp values were calculated by multivariate logistic regression adjusted by the most important clinical and epidemiological characteristics (see “Statistical analysis” section).
